Finally, about 2–15% of patients treated with EGFR-TKIs develop a histological transformation from adenocarcinoma to small cell lung cancer (SCLC), or rarely to squamous carcinoma, acquiring resistance to EGFR-TKIs. The gene discussed is EGFR; the disease is small cell lung carcinoma.